KoreaTechToday - Korea's Leading Tech and Startup Media Platform
  • Topics
    • Naver
    • Kakao
    • Nexon
    • Netmarble
    • NCsoft
    • Samsung
    • Hyundai
    • SKT
    • LG
    • KT
    • Retail
    • Startup
    • Blockchain
    • government
  • Topics
    • Naver
    • Kakao
    • Nexon
    • Netmarble
    • NCsoft
    • Samsung
    • Hyundai
    • SKT
    • LG
    • KT
    • Retail
    • Startup
    • Blockchain
    • government
No Result
View All Result
KoreaTechToday - Korea's Leading Tech and Startup Media Platform
No Result
View All Result
Home Celltrion

Celltrion to Establish China’s Biggest Biologics Plant

 1,388 total views,  1 views today

KoreaTechToday Editor by KoreaTechToday Editor
PUBLISHED: January 21, 2020 UPDATED: January 22, 2020
in Celltrion, China, Healthcare
0
celltrion

Hubei provincial government official Ma GuoQiang (right) discussing business with Celltrion’s Vice Chairman Kee Woo-sung (left) in Wuhan, China. / photo courtesy by Celltrion

Celltrion announced on Tuesday that the company would establish its first plant in Wuhan, China, stating that the facility would be China’s biggest biologics plant. The company hopes to develop and manufacture biologic drugs for the Chinese market at this Wuhan plant.

Celltrion is a biopharmaceutical company that develops, markets, and distributes biological medicines. The company, headquartered in Incheon, South Korea, aims to contribute to the improvement of patient welfare and access to healthcare by providing innovative biologics to the world.

Wuhan possesses a geographical advantage in shipping its products to the whole country. The city also houses over 300 significant research and development facilities making it a fast-growing bioindustry cluster.

The Hubei provincial government gave full support to the Celltrion Group in building a facility that would be able to manufacture 120,000 liters of biologic drugs. Currently, China’s largest facility can only produce 5,000 liters.

The Celltrion Group, through its existing cash reserves and outside investors, assigned a budget of more than 600 billion won ($514 million) until 2025.

Also, underway is the development of a direct logistics network for the company’s biosimilar products targeting China, being the world’s second-largest healthcare market.

Celltrion hopes to sign contracts for manufacturing organization deals with local biotechs.

Since 2017, China’s National Reimbursement List added several biologic drugs with local healthcare policy watchers, saying that the addition may be a forerunner to an increase in biologic drug demand in the country.

The biopharmaceutical company stated it is observing the changing trends in China’s policies, wanting to continuously export its existing biosimilars such as Remsima, Herzuma, and Truxima, in addition to other future biosimilars.

Celltrion recently developed a new type of biosimilar named Humira. The company also intends to target the diabetes treatment market with an insulin biosimilar.

The Wuhan plant would be Celltrion’s first business venture in China, holding a groundbreaking ceremony for the facility in April this year.

What’s your thoughts?
+1
0
+1
0
+1
0
+1
0
+1
0
+1
0
+1
0
Tags: biologics plantCelltrionchinadrugWuhan

Related Posts

GC Biopharma to launch first-in-class rare disorder medications in the global market
Healthcare

GC Biopharma to launch first-in-class rare disorder medications in the global market

March 2, 2023
INTIN introduces new digital healthcare products to improve quality of life
Healthcare

INTIN introduces new digital healthcare products to improve quality of life

November 27, 2021
Intin, a digital healthcare startup, honored with the ‘CES Innovation Award’ for technological prowess in healthcare
Healthcare

Intin, a digital healthcare startup, honored with the ‘CES Innovation Award’ for technological prowess in healthcare

November 20, 2021
SK Innovation Signs a Deal With Chinese EV Market Player for Battery Supply
Battery

SK Innovation Signs a Deal With Chinese EV Market Player for Battery Supply

September 9, 2021
Celltrion pushes for broader use of its COVID-19 treatment 
Celltrion

Celltrion pushes for broader use of its COVID-19 treatment 

August 12, 2021
Hyundai Mobis presented M.Brain, the world’s first in-vehicle brainwave measuring healthcare technology, reducing drowsiness-caused vehicular accidents.
Healthcare

Hyundai Mobis Unveils World’s 1st In-Vehicle Brainwave Tech M.Brain

July 24, 2021
No Result
View All Result

Follow Us

FREE NEWSLETTER




PRODUCTS

Most Popular

  • 5 Best Korean to English Translation Apps

    0 shares
    Share 0 Tweet 0
  • Top South Korean Tech Products to Look Out for in 2021

    0 shares
    Share 0 Tweet 0
  • Robots to help Police Patrol in South Korea

    0 shares
    Share 0 Tweet 0
  • 5 All-Time Best Rom-Com K-Dramas to Watch

    0 shares
    Share 0 Tweet 0
  • South Korea plans Urban Air Mobility Air Taxi services by 2025

    0 shares
    Share 0 Tweet 0
  • SK On to introduce South Korea’s first LFP Battery Prototype

    0 shares
    Share 0 Tweet 0
  • South Korea to commercialize Quantum Cryptography Communications

    0 shares
    Share 0 Tweet 0
  • Top Eight Promising EdTech Startup Companies in South Korea

    0 shares
    Share 0 Tweet 0
  • Netmarble subsidiary Metaverse Entertainment’s K-Pop virtual girl band MAVE has a smashing online debut

    0 shares
    Share 0 Tweet 0
  • KT Continues to Accelerate Its ‘Digico’ Transformation

    0 shares
    Share 0 Tweet 0
  • About Us
  • Account Page
  • application form
  • Cookie policy
  • Default Redirect Page
  • homepage
  • Login
  • login form
  • LogOut
  • Newsletter
  • Privacy Policy
  • Register
  • Reset Password
  • Sample Page
  • Subscription Plan
  • Terms of Use
  • test
  • test
  • testpage
  • TOS Page
  • Visitor Inside User Page

Copyright © 2023 KoreaTechToday | About Us | Terms of Use |Privacy Policy |Cookie Policy| Contact : press@koreatechtoday.com |

No Result
View All Result
  • Topics
    • Naver
    • Kakao
    • Nexon
    • Netmarble
    • NCsoft
    • Samsung
    • Hyundai
    • SKT
    • LG
    • KT
    • Retail
    • Startup
    • Blockchain
    • government

Copyright © 2023 KoreaTechToday | About Us | Terms of Use |Privacy Policy |Cookie Policy| Contact : press@koreatechtoday.com |